Bone Biologics Corp Stock Shares Owned By Institutions
| BBLGW Stock | USD 27.80 0.00 0.00% |
Bone Biologics Corp fundamentals help investors to digest information that contributes to Bone Biologics' financial success or failures. It also enables traders to predict the movement of Bone Stock. The fundamental analysis module provides a way to measure Bone Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bone Biologics stock.
Bone | Shares Owned By Institutions |
Bone Biologics Corp Company Shares Owned By Institutions Analysis
Bone Biologics' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Bone Shares Owned By Institutions Driver Correlations
Understanding the fundamental principles of building solid financial models for Bone Biologics is extremely important. It helps to project a fair market value of Bone Stock properly, considering its historical fundamentals such as Shares Owned By Institutions. Since Bone Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bone Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bone Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 0.0% of Bone Biologics Corp are shares owned by institutions. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Sign In To Macroaxis Now
Sign In To MacroaxisSign in to explore Macroaxis' wealth optimization platform and fintech modules |
| All Next | Launch Module |
Bone Biologics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bone Biologics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bone Biologics' managers, analysts, and investors.Environmental | Governance | Social |
Bone Fundamentals
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.57 | ||||
| Number Of Shares Shorted | 273 | ||||
| EBITDA | 479.57 K | ||||
| Net Income | (8.95 M) | ||||
| Cash And Equivalents | 4.44 K | ||||
| Total Debt | 831.4 K | ||||
| Book Value Per Share | 5.44 X | ||||
| Cash Flow From Operations | (9.56 M) | ||||
| Earnings Per Share | (0.14) X | ||||
| Beta | 0.74 | ||||
| Total Asset | 3.74 M | ||||
| Retained Earnings | (80.91 M) | ||||
| Working Capital | 2.91 M | ||||
| Net Asset | 3.74 M |
About Bone Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bone Biologics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bone Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bone Biologics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.